Hosted on MSN9h
Keymed’s Stapokibart approved by NMPA for seasonal allergic rhinitis
China's National Medical Products Administration (NMPA) has approved Keymed Biosciences’ supplemental new drug application ...
emjreviews.com3d
NICE Endorses First-of-Its-Kind Allergic Rhinitis Treatment
Discover how a newly recommended immunotherapy works by gradually increasing the body’s resistance to house dust mites.
Medscape6d
Combination Nasal Steroid–Antihistamine Is More Effective Than Either Agent Alone
For patients with allergic rhinitis, twice-daily azelastine plus ... all treatments were administered as one spray twice daily to preserve blinding. The studies were sponsored by a company that ...
Daily2h
Lupin bags USFDA nod for Ipratropium Bromide Nasal Solution for rhinorrhea
Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...
Taiwan News3d
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
The approval is based on a multi-center, randomized, double-blind, placebo-controlled phase III study to confirm the efficacy and safety of Stapokibart injection in treatment of adult patients with ...
Drug Store News5d
Lupin receives FDA nod for generic Atrovent
Ipratropium bromide nasal solution 0.06% is indicated for symptomatic relief of rhinorrhea associated with the common cold or ...
ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of ...
pulmonologyadvisor6d
Rhinoconjunctivitis in Children With Asthma May Not Always Be Allergy Driven
Phenotyping children with asthma based on rhinoconjunctivitis symptoms shows that rhinoconjunctivitis may not always be allergy driven.
Keymed Biosciences Inc.: Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental ...